US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

43.29

+0.03220.07%

Post-market: 43.290.00000.00%16:15 EDT

Volume:17.37K

Turnover:755.83K

Market Cap:41.12M

PE:- -

High:44.03

Open:42.82

Low:42.82

Close:43.26

52wk High:56.18

52wk Low:27.62

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.86

T/O Rate:1.83%

Dividend:0.65

Dividend Rate:1.51%

ROE:--

ROA:--

PB:0.93

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Trasteel Holding S.A. Completes Acquisition of the Remaining 40% Interest in BBC Alloys S.r.l.

Mirum Advances MRM-3379 With Completed Phase 1 ADME Study

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

ArriVent says Phase 3 firmonertinib trial did not meet endpoint

Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105

BNK Banking Sets Virtual Date for 2026 Annual General Meeting

Vaxcyte data hit ‘blue-sky’ case, says Jefferies

10 Monday AM Reads

The Big Picture

Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31

Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial

The BBC’s bulletin cuts show how crowded sports broadcasting has become

BioAge Labs initiates Phase 2 trial for BGE-102

Abogen announces licensing, option agreement with Novartis

UK Prime Minister Says Iran May Be Linked to Security Incident at RAF Fairford Air Base

Verrica Pharmaceuticals to present new YCANTH data at upcoming conferences

Jade Biosciences advances JADE301 toward Phase 1 trial

Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

C4 Therapeutics Reports New Cemsidomide Myeloma Data

Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BBC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":43.2874,"timestamp":1791403200000,"preClose":43.2552,"halted":0,"volume":17369,"hourTrading":{"tag":"盘后","latestPrice":43.2874,"preClose":43.2874,"latestTime":"16:15 EDT","volume":12,"amount":519.426636,"timestamp":1791404100369,"change":0,"changeRate":0,"amplitude":0.000171},"delay":0,"changeRate":0.000744419168099928,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Post-Mkt","change":0.0322,"latestTime":"10-07 17:35:37 EDT","open":42.82,"high":44.03,"low":42.82,"amount":755831,"amplitude":0.027974,"askPrice":51.01,"askSize":100,"bidPrice":29.64,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":43.2552,"sharesOutstanding":900004,"nav":44.728,"aum":42491680.3,"dividendRate":0.01509,"bidAskSpread":0.002127,"postHourTrading":{"tag":"盘后","latestPrice":43.2874,"preClose":43.2874,"latestTime":"16:15 EDT","volume":12,"amount":519.426636,"timestamp":1791404100369,"change":0,"changeRate":0,"amplitude":0.000171},"volumeRatio":0.863082,"impliedVol":0.371,"impliedVolPercentile":0.8207},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.863082,"shares":950000,"dividePrice":0.6532,"high":44.03,"amplitude":0.027974,"preClose":43.2552,"low":42.82,"week52Low":27.62,"pbRate":"0.93","week52High":56.18,"institutionHeld":0,"latestPrice":43.2874,"eps":0,"divideRate":0.01509,"volume":17369,"delay":0,"ttmEps":0,"open":42.82,"prevYearClose":38.56,"prevWeekClose":44.5638,"prevMonthClose":46.2948,"prevQuarterClose":46.2948,"fiveDayClose":46.2948,"twentyDayClose":51.51,"sixtyDayClose":51.5732},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673101280","title":"Press Release: Trasteel Holding S.A. Completes Acquisition of the Remaining 40% Interest in BBC Alloys S.r.l.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673101280","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673101280?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:05","pubTimestamp":1791403500,"startTime":"0","endTime":"0","summary":"LUGANO, Switzerland and BERTRANGE, Luxembourg, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Trasteel Holding S.A. (\"Trasteel\" or the \"Company\"), a global steel trading and industrial group (the \"Group\") headquar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","SZZL","CEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011746","title":"Mirum Advances MRM-3379 With Completed Phase 1 ADME Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011746","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011746?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390610,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals ($MIRM) announced an update on their ongoing clinical study. Mirum Pharmaceuticals, Inc. is running a Phase 1 trial called “A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mirum-advances-mrm-3379-with-completed-phase-1-adme-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mirum-advances-mrm-3379-with-completed-phase-1-adme-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRM","ADME","BBC","BK4192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673656016","title":"Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673656016","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673656016?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:00","pubTimestamp":1791381622,"startTime":"0","endTime":"0","summary":"WSW, NY, October 7th, 2026, FinanceWire The former Gilead and Amgen commercial leader takes her seat as Entera’s Phase 3 trial nears its init...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/former-gilead-and-amgen-commercial-leader-laura-hamill-just-joined-entera-nasdaq-entx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/former-gilead-and-amgen-commercial-leader-laura-hamill-just-joined-entera-nasdaq-entx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","NQmain","PSQ","LU1983299246.USD","ONEQ","SQQQ","LU0320765992.SGD","TBXU","IE00BFTCPJ56.SGD","QID","03086",".IXIC","TQQY","LU0122379950.USD","LU0889565916.HKD","NVIW.SI","QLD","BK4534","QQQJ","BK4599","QQQ","QQQE","AMGN","TECS","IYW","JEPQ","IE0002141913.USD","BK4139","PSIL","PJP","PBE","BBH","MNQmain","QQQA","QQQM","QYLG","ENTX","BBC","BIB","BK4566","LU1057294990.SGD","FTEC","IBBQ","QQQY","IE00BJT1NW94.SGD","IBB","IE0009355771.USD","QDTE","GPIQ","NDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051961","title":"ArriVent says Phase 3 firmonertinib trial did not meet endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051961?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:13","pubTimestamp":1791292413,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, loca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","AVBP","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705514","title":"Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705514","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705514?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:35","pubTimestamp":1791286532,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","MEDX","GDOC","NVIB","IDNA","BK4139","KAIR","HYLG","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673080367","title":"BNK Banking Sets Virtual Date for 2026 Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673080367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673080367?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:57","pubTimestamp":1791244657,"startTime":"0","endTime":"0","summary":"An update from BNK Banking Corporation Limited ( ($AU:BBC) ) is now available. BNK Banking Corporation Limited has announced that its 2026 Annual G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bnk-banking-sets-virtual-date-for-2026-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bnk-banking-sets-virtual-date-for-2026-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673088978","title":"Vaxcyte data hit ‘blue-sky’ case, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673088978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673088978?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:55","pubTimestamp":1791208523,"startTime":"0","endTime":"0","summary":"After Vaxcyte (PCVX) announced topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating its VAX-31 31-valent pneumococcal conjugate v...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-data-hit-blue-sky-case-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-data-hit-blue-sky-case-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PCVX","IE0009354923.USD","BK4139","LU0053671581.USD","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707819","title":"10 Monday AM Reads","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707819","media":"The Big Picture","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707819?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:30","pubTimestamp":1791196218,"startTime":"0","endTime":"0","summary":"Private Equity Has a Problem. Uncle Sam Says Your Wallet Can Fix It.: A government proposal would help fund managers sell alternative investments to a much wider audience. Wall Street’s problem becomes Main Street’s opportunity, or vice versa.‘Things may get ugly’: Meta’s new AI Muse is about to make the internet more annoying: Thomas Germain: the web was built for humans, and Meta’s agent is about to start using it on their behalf. Someday we’ll redesign the internet for tools like this. Until then, you’re in for a wild ride.  see also Meta open sources code to let you make Muse AI gadgets: Meta now lets you connect Muse to your own hardware to put on your displays or a Raspberry Pi.Jay Peters: Meta now lets anyone build hardware around its Muse agent, suggesting projects like an E Ink reminder display. . Paint it black: Efficacy of increased wind turbine rotor blade visibility to reduce avian fatalities,.Painting one of the blades of","market":"nz","thumbnail":"https://ritholtz.com/wp-content/uploads/2030/07/vix.png","type":0,"news_type":0,"thumbnails":["https://ritholtz.com/wp-content/uploads/2030/07/vix.png"],"rights":{"source":"ritholtz_highlight","url":"https://ritholtz.com/2026/10/10-monday-am-reads-495/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ritholtz.com/2026/10/10-monday-am-reads-495/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ritholtz_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709724","title":"Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709724","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709724?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:10","pubTimestamp":1791195037,"startTime":"0","endTime":"0","summary":"Vaxcyte (PCVX) announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-announces-positive-results-from-opus-1-phase-3-trial-of-vax-31-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-announces-positive-results-from-opus-1-phase-3-trial-of-vax-31-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","LU0053671581.USD","BK4139","IE0009354923.USD","PCVX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776067","title":"Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776067?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:22","pubTimestamp":1791156146,"startTime":"0","endTime":"0","summary":"An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics reported new analyses from its Phase 2 trial of AT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alteritys-ath434-phase-2-data-strengthen-case-for-msa-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alteritys-ath434-phase-2-data-strengthen-case-for-msa-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672722351","title":"The BBC’s bulletin cuts show how crowded sports broadcasting has become","url":"https://stock-news.laohu8.com/highlight/detail?id=2672722351","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672722351?lang=en_us&edition=fundamental","pubTime":"2026-10-04 12:00","pubTimestamp":1791086400,"startTime":"0","endTime":"0","summary":"The BBC’s decision to drop sport bulletins is lesson for sector The BBC’s decision to drop lunchtime and overnight sports bulletins from its news channel has rightly had a few journalists loosening their collars. Savings must be found, but will people miss the content?Anyone who follows football transfers spends more time on Fabrizio Romano’s social media channels than most of their relatives. And football fans will happily spend an hour listening to someone who knows their club down to the physio’s second cousin twice removed. Getting them to wait until lunchtime for an update, however, feels positively archaic when they have already spent the morning arguing about it on X.Itchy trigger fingerLive rights are still a formidable advantage. Broadcasters can pull millions of eyeballs onto a TV screen at the same time, with the scale and production expertise that blow independent channels out of the water. But the BBC are also bound to reach beyond the most zealous of fans. A YouTube chann","market":"us","thumbnail":"https://www.cityam.com/wp-content/uploads/2026/10/GettyImages-2199824975-e1790934502509.jpg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2026/10/GettyImages-2199824975-e1790934502509.jpg?w=824&h=463&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/the-bbcs-bulletin-cuts-show-how-crowded-sports-broadcasting-has-become/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/the-bbcs-bulletin-cuts-show-how-crowded-sports-broadcasting-has-become/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672741591","title":"BioAge Labs initiates Phase 2 trial for BGE-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2672741591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672741591?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:54","pubTimestamp":1790974488,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. ( ($BIOA) ) just unveiled an update. BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-labs-initiates-phase-2-trial-for-bge-102?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-labs-initiates-phase-2-trial-for-bge-102?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BBC","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672163957","title":"Abogen announces licensing, option agreement with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2672163957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672163957?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:10","pubTimestamp":1790935812,"startTime":"0","endTime":"0","summary":"Abogen Biosciences, a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agree...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abogen-announces-licensing-option-agreement-with-novartis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abogen-announces-licensing-option-agreement-with-novartis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","BK4585","JDOC","AGNG","IBB","BK4505","BBP","RSPH","FWD","XT","IE0009354923.USD","BK4139","LNGR","BBC","IEIH","RNA","BK4588","DARP","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152338036","title":"UK Prime Minister Says Iran May Be Linked to Security Incident at RAF Fairford Air Base","url":"https://stock-news.laohu8.com/highlight/detail?id=1152338036","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152338036?lang=en_us&edition=fundamental","pubTime":"2026-10-01 01:12","pubTimestamp":1790788330,"startTime":"0","endTime":"0","summary":"UK Prime Minister Burnham has stated that the UK government believes the Iranian government was involved in a security incident at RAF Fairford air base.Five men were arrested on Sunday on suspicion...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671204298","title":"Verrica Pharmaceuticals to present new YCANTH data at upcoming conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2671204298","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671204298?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:36","pubTimestamp":1790771793,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals (VRCA) announced that it will present posters on a new analysis of Phase 3 trials of YCANTH and an encore presentation of d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-to-present-new-ycanth-data-at-upcoming-conferences-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-to-present-new-ycanth-data-at-upcoming-conferences-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRCA","PSIL","BK4007","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209135","title":"Jade Biosciences advances JADE301 toward Phase 1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209135","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209135?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:28","pubTimestamp":1790767727,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Jade Biosciences ( ($JBIO) ). On September 30, 2026, Jade Biosciences reported preclinical data for JADE301, sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jade-biosciences-advances-jade301-toward-phase-1-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jade-biosciences-advances-jade301-toward-phase-1-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JBIO","BK4539","BK4139","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671116862","title":"Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2671116862","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671116862?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:49","pubTimestamp":1790682559,"startTime":"0","endTime":"0","summary":"The latest update is out from Invivyd ( ($IVVD) ). Invivyd, Inc. is a clinical-stage biotech company developing antiviral monoclonal antibodies, le...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/invivyd-phase-3-covid-antibody-trial-shows-superior-safety?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/invivyd-phase-3-covid-antibody-trial-shows-superior-safety?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670605236","title":"MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2670605236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670605236?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:15","pubTimestamp":1790590507,"startTime":"0","endTime":"0","summary":"MediciNova (MNOV) announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyce...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","PSIL","BK4139","IDNA","NVIB","GDOC","MEDX","BBC","MNOV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442737","title":"C4 Therapeutics Reports New Cemsidomide Myeloma Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442737?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:27","pubTimestamp":1790335653,"startTime":"0","endTime":"0","summary":"C4 Therapeutics ( ($CCCC) ) has issued an announcement. On September 25, 2026, C4 Therapeutics presented new biomarker data from its Phase 1 trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/c4-therapeutics-reports-new-cemsidomide-myeloma-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/c4-therapeutics-reports-new-cemsidomide-myeloma-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CCCC","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670492925","title":"Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492925","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492925?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:31","pubTimestamp":1790267475,"startTime":"0","endTime":"0","summary":"Viking Therapeutics ($VKTX) announced an update on their ongoing clinical study. Viking Therapeutics, Inc. is running a Phase 1 trial called “A Pha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/viking-therapeutics-advances-vk2735-obesity-trial-keeping-vktx-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/viking-therapeutics-advances-vk2735-obesity-trial-keeping-vktx-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","OZEM","BK4585","VKTX","THNR","BK4599","BBC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":167,"code":"91000000","status":"200"}]}}